McCLEC, a robust and stable enzymatic based microreactor platform by Conejero-Muriel, Mayte et al.
Lab on a Chip
PAPER
Cite this: Lab Chip, 2015, 15, 4083
Received 3rd July 2015,
Accepted 20th August 2015
DOI: 10.1039/c5lc00776c
www.rsc.org/loc
McCLEC, a robust and stable enzymatic based
microreactor platform†
Mayte Conejero-Muriel,a Isaac Rodríguez-Ruiz,b Sergio Martínez-Rodríguez,c
Andreu Lloberab and José A. Gavira*a
A microfluidic chip for cross-linked enzyme crystals (McCLEC) is presented and demonstrated to be a sta-
ble, reusable and robust biocatalyst-based device with very promising biotechnological applications. The
cost-effective microfluidic platform allows in situ crystallization, cross-linking and enzymatic reaction
assays on a single device. A large number of enzymatic reuses of the McCLEC platform were achieved and
a comparative analysis is shown illustrating the efficiency of the process and its storage stability for more
than one year.
Introduction
The use and development of enzymes as robust biocatalysts is
one of the main challenges in biotechnology.1 Enzymes are a
specific kind of proteins involved in the catalysis of essential
biochemical reactions in life processes. Biocatalysis allows the
mild and selective formation of products using isolated
enzymes. Compared to chemical methods, biocatalysis shows
excellent chemo-, regio- and stereoselectivity while retaining a
small environmental footprint. Enzymes are widely applied in
many different industries such as food processing (for
humans and animals),2 pharmaceuticals,3,4 materials process-
ing (textiles, paper, detergents, etc.), waste treatment and
also biofuel production.5 A similar level of development can
be found in the application of enzymes in biosensor
technologies.6–8 However, there are also drawbacks in
enzyme-catalyzed reactions. They can exhibit a slow reaction
rate, be unstable in practical operational conditions (such as
high temperatures or the use of organic solvents), their stor-
age stability (or shelf life) can be poor and the downstream
processing can be complex. At the industrial level these
drawbacks are typically overcome by the production of
immobilized enzymes to enhance stability, robustness and
solubility.9
Immobilization is aiming to be a very powerful tool to
improve the characteristic properties of enzymes (stability,
activity, specificity and selectivity), allowing continuous
operation, control of the enzymatic reaction and enzyme
recovery and reuse.10,11 Among all the immobilization tech-
niques, the cross-linking of enzymes in their crystalline
state, cross-linked enzyme crystals (CLECs), or as aggre-
gates, cross-linked enzyme aggregates (CLEAs), are being
explored. Although CLEAs are the easier and economically
beneficial way to produce these highly active materials com-
pared to CLECs, their particle size and distribution are dif-
ficult to control and they are less robust. CLECs, described
for the first time in 1964 by Quiocho and Richards,12 are
prepared by the crystallization of the enzyme followed by
cross-linking of the micro-crystals produced by using
bifunctional reagents.13 In contrast to enzymes immobilized
by classical techniques (bounded to a support or encapsu-
lated), carrier-free immobilized enzymes in the form of
CLECs present numerous advantages versus carrier-bound
or free enzyme: i) volumetric activities 10 to 1000 (U g−1)
times higher, as CLECs are basically pure protein, with a
high concentration of enzyme per volume unit (any carrier
inevitably suffers from dilution of volumetric and specific
activities as carriers account for 90% to >99% of the mass
or volume of the catalyst;14 ii) higher stability against
unnatural conditions (high temperature, organic solvents,
etc.), as the enzyme crystal formation and the additional
cross-linking process prevent denaturation, unfolding or
degradation of the enzyme by proteases;14 and iii) in partic-
ular cases even higher selectivity. Furthermore, CLECs can
be easily lyophilized and indefinitely stored at room tem-
perature and their insoluble nature facilitates the isolation,
recycling and reuse of the enzyme.13 Therefore, the use of
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CLECs for biosensing applications has a ground-breaking
and yet unexplored potential when considering their actual
storage limitations (biosensors cannot be stored for long
periods due to quick denaturation of the enzymes) and
shelf life, which usually lasts just a few days or weeks in
the best situation.
In spite of all the advantages mentioned above, crystalli-
zation is hitherto identified as the limiting step for the
production of CLECs. However, taking advantage of micro-
fluidics, it is possible to provide a unique environment for
the production and immobilization of enzyme crystals.
Microfluidics offers clear advantages over more conven-
tional systems, such as a dramatic reduction of reagent
consumption, shorter analysis time, separation efficiency
and high resolution and sensitivity in detection.15–19 Micro-
fluidics has also been applied in protein crystallization20,21
and enzymatic assays, providing sample and reagent vol-
umes smaller than those used in robotic systems,22–24 and
exploiting the short diffusion lengths inside the devices to
have faster reaction velocities.25–27 Additionally, this sci-
ence field offers the attractive possibility of combination of
chemical processes and biological assays in the same
device.22,28 In this way, and due to the reduction of volume
reagents (i.e. cost-effective), in terms of costs, micro-
fluidics, or lab-on-a-chip technology,29,30 is offered as a
powerful and high-throughput approach in a vast number
of applications such as molecular biology, protein analysis,
immunoassays, diagnosis and drug development.31–40
Indeed, the use of enzymatic catalytic reactions under
microfluidic flow conditions reveals a promising technology
with a series of strategic advantages, such as dramatic
enhancement of surface/volume ratios and spatial/temporal
reaction control, continuous processing at smaller scales,
improved energy efficiency and mass transport in
multiphase reactions or faster process development, which
are putting it into the spotlight of vast and broad applica-
tions, speeding up the discovery and development of new
biotechnological applications.41
In this work we propose the use of cross-linked enzyme
crystals (CLECs) for enzymatic catalytic reactions as a sta-
ble, reusable and robust catalyst with very promising
applications in the synthesis of high-value products as
well as in biosensing. For this purpose, and taking advan-
tage of a common technology widely used in biosensing
applications, a microfluidics platform, McCLEC (micro-
fluidic chip for cross-linked enzyme crystals), has been
conceived for performing in situ and spatially controlled
enzyme crystallization from solution and to cross-link the
crystals that can repetitively be used or fed with the
appropriated substrate. As a proof of concept, the crystalli-
zation process, subsequent cross-linking and in situ enzy-
matic reaction of two proteins is presented here: lysozyme
as a model protein and a formamidase as a protein of
interest for the pharmaceutical industry for either the




PDMS Sylgard 184 elastomer kit was supplied by Dow
Corning (Midland, MI, USA). SU-8 negative tone photoresist
and propylene glycol methyl ether acetate developer (PGMEA)
were supplied by MicroChem Corp. (Newton, MA, USA).
Chicken egg-white lysozyme (lysozyme) was purchased as
a lyophilized powder from Sigma (L6876). Bacillus cereus
formamidase (FASE) was produced in a two-step purification
in the lab. Glutaraldehyde (G7651) and formamide (F4761)
were purchased as solutions from Sigma and 4-nitrophenyl-β-
D-N,N′,N″,-triacetylchitotriose from Santa Cruz Biotechnology
(sc-220973A). Ammonia kit was purchased from R-Biopharm
(11112732035).
McCLECs design, concept and fabrication
McCLECs were fabricated in one single step by casting of
PDMS in a 2-level SU-8 master42 (see the ESI† for details and
Fig. S1). Their global design is shown in Fig. 1 and it is
described as follows: two different inlet ports (number 1 in
Fig. 1a) permit the mixing of up to 2 different solutions if
required, which merge downstream in a single channel con-
figured as a passive zigzag mixer (number 3 in Fig. 1a) and
Fig. 1 Images and schematics of McCLECs. a) General view: (1) inlet
ports; (2) outlet port; (3) passive zigzag mixer; (4) serpentine channel
for droplet storage; (5) PDMS filters. Inset on the left: cross section
depicting the layout of the solution trapping system (microwell array)
over the microfluidic channel. b) Detail of the microwell array and the
PDMS filter. c) Image of the PDMS filter. d) Operation of the solution
trapping system during the injection of a red dye solution. The
meniscus of the flowing solution is observed when emptying the
microfluidic device, while the solution trapping system retains
nanolitre-sized droplets in the microwell array.
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which is implemented in the design for providing fast
homogenization of the mixtures.43,44 Subsequently, a serpen-
tine channel with a section of 250 μm × 500 μm (number 4
in Fig. 1a) allows the storage of thousands of nanolitre drop-
lets in each microdevice by means of a solution trapping sys-
tem. A detail of the system, consisting of an array of micro-
wells with a volume of 2 nL each (100 μm × 100 μm section,
200 μm high) can be seen in Fig. 1b. The array is constructed
over a main serpentine channel but at a different height
(inset in Fig. 1a). The serpentine channel containing these
microwell structures provides a total reaction volume of ≈17
μL, with the total McCLEC volume being ≈20 μL. The opera-
tion of the trapping system will be described later in the text.
Additionally, a filter of PDMS was fabricated in the same sin-
gle cast-molding step, which defines the microfluidic struc-
ture and wells (number 5 in Fig. 1a and b). The filter is
located before and after the serpentine channel to prevent
any possible non-fixed crystal or crystal aggregate larger than
30 μm to be dragged by the injected solutions, either during
the cross-linking of the crystals or during the subsequent
enzymatic catalytic reaction. A detail of the PDMS filter is
presented in Fig. 1c. Finally the serpentine channel ends up
in an outlet port (number 2 in Fig. 1a), which is positioned at
the same plane of the inputs to facilitate microscope access
to the reactor region.
Protein preparation and production
Lysozyme was dissolved and dialyzed in 50 mM sodium ace-
tate, pH 4.5. B. cereus formamidase (FASE) was expressed in
E. coli BL21 (DE3) as a fusion protein with a C-terminal
hexahistidine tag and purified from bacterial lysates to
homogeneity in two steps: i) affinity chromatography (15 ml
bed volume, GE Healthcare) in 50 mM Na2HPO4 and 300 mM
NaCl buffer and ii) size-exclusion chromatography (Superdex
200 column; GE Healthcare) in 20 mM Tris-HCl, pH 8.0. The
protein was then concentrated using a Centricon centrifuga-
tion system with a 10 kDa molecular mass cut-off membrane.
Based on SDS-PAGE experiments, the purity of the recombi-
nant protein was estimated to be greater than 95%.
Crystallization experiments
McCLECs were tested for crystallization with lysozyme as a
model protein and FASE as an enzyme with potential biotech-
nological applications.
An initial grid screening for lysozyme crystallization was
performed by varying the concentration of the protein from
10 to 50 mg ml−1 and that of precipitant NaCl from 1% to
10% in hanging drop experiments at 293 K. Although all the
conditions of the grid produced crystals, the most suitable
crystals in terms of size and number were obtained at a pro-
tein concentration of 20 mg ml−1 and 5% NaCl as precipi-
tant. Thus, this crystallization condition was adapted for
lysozyme crystallization in McCLECs by batch method,
obtaining tetragonal lysozyme crystals at a supersaturation
ĲC/CEquilibrium) of 4.2.
Initial crystallization conditions for FASE were obtained by
screening in capillaries of 0.3 mm inner diameter using the
counterdiffusion technique in pre-filled GCBs.45 In this case,
the precipitant was a mixture of PEGs (20% PEG 400, 15%
PEG 4000, 10% PEG 8000) in the pH range of 4.0 to 9.0 (KIT
PEG448-49, Triana S&T) and the protein was used at a con-
centration of 28 mg ml−1. Conditions were then adapted to
the batch method in two steps (Table S1 and Fig. S2†).
Firstly, the microbatch under oil method was used to reduce
the protein and precipitant concentration to a desirable
nucleation density and crystal size values by varying the pro-
tein concentration between 15 to 3.75 mg ml−1 and diluting
the precipitant cocktail from 50% to 12.5% with 100 mM
sodium acetate, pH 4.0 (Table S1†). Secondly, similar condi-
tions were used in Eppendorf-PCR tubes to produce FASE
crystals that could be further cross-linked and recovered (Fig.
S2†). The experiments were set in volumes ranging from 10
to 500 μL to study the influence on the final nucleation den-
sity and crystal size.
Crystallization experiments in McCLECs were performed
by batch technique in different steps. Initially, the McCLEC
devices were incubated with a solution containing 1% Triton
X-100 surfactant (108643 Merck Millipore) in order to modify
the highly hydrophobic PDMS surface, allowing the correct
filling of the microwell array. The crystallizing batch solution
(enzyme and precipitant) was injected to fill each McCLEC
and subsequently a soft vacuum was applied through the
outlet port, emptying the main microfluidic channel. The dif-
ference in surface energy of both the modified PDMS walls
and the injected solutions makes it possible to extract the
excess solution while keeping the microwell array filled
Fig. 2 Schematic representation of the three major steps carried out
to prepare CLECs in McCLECs. Step 1 shows the crystallization process
inside the device and examples of lysozyme crystals are depicted. Step
2 displays the cross-linking process showing the cross-linked crystals.
Finally, steps 3 and 4 respectively show the operation of the chip as an
enzymatic reactor and the final spectrophotometric detection for the
product of the reaction.
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(Fig. 2, step 1). McCLECs were stored in Petri dishes with
water reservoirs to avoid evaporation from the microwell
array.
A total of 15–30 μL of crystallizing solution was set up for
each protein; 20 mg ml−1 protein and 5% NaCl as precipitant
were used in the case of HEWL, whereas 5 mg ml−1 protein
and a polyethylene glycol mixture (10% PEG 400, 7.5% PEG
4000, 5% PEG 8000) in 100 mM sodium acetate (pH 4.0) was
used to trigger FASE crystallization. All the experiments were
performed at 293 K and observed with an optical microscope.
Pictures were acquired with a ProgRes® CapturePro 2.8 detec-
tor (JENOPTIK optical systems, GmbH).
Cross-linked enzyme crystal production
Crystals of both enzymes were cross-linked by incubating
McCLECs for 1 hour at room temperature (RT) with the corre-
sponding crystallizing solution (see above) supplemented
with 1% Ĳv/v) glutaraldehyde. Incubation time and cross-
linker concentration were both previously optimized using
SDS-PAGE (see ESI† for details and Fig. S3). An example of
cross-linked lysozyme crystals is shown in Fig. 2, step 2. Sub-
sequently, cross-linked crystals were carefully washed by
injecting at least three volumes of water into the McCLECs.
Finally the McCLECs containing cross-linked lysozyme and
FASE crystals (McCLLCs and McCLFCs, respectively) were
dried and stored at RT for several months.
Enzyme assays
Spectrophotometric determinations were carried out in a
Cary 300 UV-VIS spectrophotometer (Agilent Technologies,
Santa Clara, CA) with blank corrections for all measurements.
The enzymatic assay for lysozyme was adapted from Osawa T
experiments46,47 to be assayed colorimetrically by using nitro-
phenyl-β-D-N,N′,N″-triacetylchitotriose as substrate and the
p-nitrophenol liberated as a product of the reaction was deter-
mined at a wavelength of 400 nm. Enzymatic production of
ammonia by FASE was spectrophotometrically determined
using a commercially available ammonia determination kit
following manufacturer instructions (ammonia kit, R-Bio-
pharm, 11112732035).
CLEC activities grown inside McCLECs were determined
by reaction with 4-nitrophenyl-β-D-N,N′,N″-triacetylchitotriose
(1 mg ml−1) dissolved in 1 mM sodium phosphate, pH 9.0
(McCLLCs), and 6 mM formamide in 100 mM citrate/citric
acid, pH 6.0 (McCLFCs) (Fig. 2, step 3). Substrate-loaded
McCLECs were incubated for 2 hours at 323 K in Petri dishes
containing a water reservoir to avoid solution evaporation
from the devices. The reaction solutions were then recovered
from the devices using a micropipette, and product concen-
trations were determined spectrophotometrically as described
above (Fig. 2, step 4).
In order to compare the activity of CLECs produced both
inside and outside McCLECs, crystals for the two proteins
were produced by the batch methods, cross-linked by adding
1% glutaraldehyde directly into their mother liquor, washed,
lyophilized, weighed on a precision balance and added to the
corresponding reaction solutions (see the ESI† for details and
Fig. S4). For the reuse evaluation experiments, CLECs were
extensively washed with water after each run, dried and
stored at RT till the next use.
Results and discussion
The McCLECs presented here were specifically designed to
allow preferential crystallization into a microwell array while
allowing the mixture and flow of a solution along a micro-
fluidic channel that connects the array. This makes possible
the subsequent enzymatic reaction and the recovery of the
product if required. Although the experiments presented here
were carried out by batch method, a continuous solution
injection would transform McCLEC batch reactors into con-
tinuous flow reactors for the production of a desired product.
Additionally, it is worth mentioning that coupling an appro-
priate detection system to the McCLECs would lead to the
creation of a biosensor with the possibility of operating in
continuous mode. Although related optofluidic enzymatic
biosensors have been previously reported,24 the combination
of McCLECs with the multiple path photonic lab on a chip
concept48 for the creation of a continuous photonic sensing
platform is yet to be reported and represents a substantial
advance, since it provides unmatchable advantages in terms
of robustness, sensitivity and stability. The validation and
proof of feasibility for these biotechnological reactor/sensor
approaches are presented below.
McCLEC validation
In order to prove the McCLEC concept, lysozyme was selected
since it is a highly characterized enzyme from both the crys-
tallization and enzymatic points of view.49–52 Tetragonal lyso-
zyme crystals were grown in McCLEC microwells using the
batch method. Crystals appeared within 8–12 h at 293 K
(Fig. 3A), and after equilibration (2–4 days) they were cross-
linked (Fig. 3B), washed and dried. The devices were stored
at RT for more than one year without noticeable loss of activ-
ity (see below).
Since the microchip was not conceived to be able to mea-
sure the total amount of protein crystallized, several
McCLLCs (cross-linked lysozyme crystals in McCLEC) were
prepared (chips 1 to 3) and employed to study the three main
variables used to carry out the enzymatic reaction, i.e. sub-
strate concentration, temperature and reaction time. Two
substrate concentrations (0.5 mg ml−1 and 1 mg ml−1), three
temperatures (293 K, 315 K and 325 K) and three reaction
times (2 h, 3.5 h and 12 h) were tested and the extension of
the reaction followed by the production of p-nitrophenol.
Optimal operational conditions (>95% substrate conversion
within 2 h) were achieved at 325 K using 1 mg ml−1
substrate.
The robustness of the McCLLCs was evaluated by
reutilization of different chips (once a day) by means of two
approaches: i) after shelf storage at RT for 1 year (chips 1–3)
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and ii) with freshly prepared devices (chips 4–9) (Fig. 3C).
Both shelf-stored and freshly prepared CLLC devices were
fully operative with no detectable loss of activity after 20
reuses (see also Fig. S5A of the ESI†). Observed deviations
may be attributed to either the preparation of the substrate
or the recovery and determination of the product concentra-
tion. Both experiments validate the McCLECs as a cost-
effective preparation of a novel type of auto-supported enzy-
matic system.
McCLECs application
To address the applicability of the microfluidic devices in a
potential biotechnological application, formamidase (FASE)
was chosen for setting up McCLFCs (cross-linked FASE crys-
tals in McCLEC). FASE is a member of the nitrilase superfam-
ily, a group of enzymes that play a key role in chemical and
pharmaceutical engineering and bioremediation.53 Despite
the natural function of FASE in the hydrolysis of formamide,
this enzyme also shows acyl-transferase activity, allowing the
production of acetohydroxamic acid (Lithostat®),54 a potent
inhibitor of urease, indicated in patients with chronic urea-
splitting urinary infection.
FASE crystallization conditions used in McCLFCs were
determined from batch experiments at 293 K (5 mg ml−1 pro-
tein, 10% PEG 400, 7.5% PEG 4000, 5% PEG 8000, and 100
mM sodium acetate, pH 4.0, as precipitant). Under these con-
ditions, FASE crystals were obtained in 24 h. In this case, the
number and size of FASE crystals were more disperse than in
the case of tetragonal lysozyme (Fig. 4A–D).
Three different sets of McCLFCs (devices 1–3, 4 and 5–7)
were independently prepared to study their reuse capability.
Considering an effective trapped solution volume of 4 μL
Fig. 3 Lysozyme crystallization, cross-linking and CLLC reutilization in
microfluidic chips. A) Lysozyme crystals grown in 8–12 h at 293 K
inside McCLEC microwells. Crystallization experiments were set up by
batch method with a supersaturated protein solution at 20 mg ml−1
and 5% NaCl as precipitant. B) CLLCs produced by incubating for 2
hours with 1% glutaraldehyde at RT. D) Results of enzymatic assays
with 9 different McCLLCs. Each coloured bar represents the average of
the total number of reuses of independent McCLLCs with its standard
deviation. Chips 1–6 had been stored for 8 months and dried at room
temperature until use for enzymatic assays, and devices 7–9 one year
after the initial proofs.
Fig. 4 FASE crystallization, cross-linking and enzymatic assays in
microfluidic devices. A) FASE crystals grown in 24 h at 293 K by batch
method in McCLECs with a supersaturated protein solution of 5 mg
ml−1 and a polyethylene glycol mixture (20% PEG 400, 15% PEG 4000,
10% PEG 8000) in 100 mM sodium acetate (pH 4.0) as crystallizing
agent. B) McCLFCs produced by incubation of the crystals for 1 h at
room temperature with 1% glutaraldehyde. C) and D) Photographs of
CLFCs after 20 enzymatic reuses. E) Results of enzymatic assays with 6
different McCLFCs. Each coloured bar represents an enzymatic reuse
of the McCLFCs in each device. Devices 1–3 had been stored for
8 months and dried at room temperature until use for enzymatic
assays and devices, 4 and 5–7, 3 months after the initial proofs.
























































































4088 | Lab Chip, 2015, 15, 4083–4089 This journal is © The Royal Society of Chemistry 2015
and a protein concentration of 5 mg ml−1, the maximum
amount of protein that could be precipitated in each
McCLFC was ~20 μg. Devices 1–3 (first set) were initially
used to optimize the operational conditions while keeping
the substrate concentration constant at 6 mM formamide.
The best reproducible results were obtained with 2 h of sub-
strate incubation at 313 K. Following a protocol similar to
that with CLLC, devices 1–3 were thoroughly washed and
stored at RT for 8 months before the reuse experiments
while the other two sets were freshly prepared. From the
three devices used to prepare the second set only in one of
the devices did the obtained crystals remain stable after the
cross-linking. Therefore a third set of McCLFC was prepared
from a new purification preparation. The reuse activity of
the three sets was determined during 17 cycles (1–3), 23
cycles (4) and 21 cycles (5–7). No difference in the mor-
phology of the crystals was observed after the reuse
(Fig. 4C and D). As can be observed in Fig. 4E, device 4
showed a lower activity level than the other two sets. These
differences, which should not be surprising when working
with different protein preparations, arise as the main cause
of the inter-reproducibility of the measured activity (see also
Fig. S5B of the ESI†). Further visual inspection of the
McCLFCs indicates, as expected, that the number and shape
of FASE crystals in each set were different and therefore
could be directly related to the catalyst effective concentra-
tion translated as a different level of activity. On the other
hand, their stability after several reaction cycles and storage
does not seem to be affected.
Conclusions
In conclusion, a microfluidic system (McCLEC) is proposed
as a simple and unique platform for in situ protein crystalli-
zation, cross-linked enzyme crystal production and enzy-
matic catalytic bioreaction performance. The McCLEC con-
cept has been validated with two different proteins: a
commercial protein, lysozyme, which is easy to crystallize
and well characterized, and a protein of pharmaceutical
interest, a formamidase, produced and purified for this
study. CLECs of both proteins were obtained inside
McCLECs and their application as a biocatalyst was studied.
Reuse of CLECs has been shown possible, thus decreasing
the economic costs of the enzymatic reaction, presenting
McCLECs as a robust and cost-effective technology. Further-
more, the McCLECs have shown excellent long-term shelf
life and storage capabilities at room temperature (up to one
year), not only freshly stored but also stored after several
reaction cycles, without a decrease in the enzymatic activity.
Therefore, McCLECs offer a stable, robust and durable plat-
form for enzymatic catalysis, which can be used not only for
enzyme characterization and high-value product synthesis
but also as a sensing platform when coupled to a detection
system.
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